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Abstract
Background: Both type I interferon (IFN), also known as IFN-a and tumor necrosis factor alpha (TNF-a) have been implicated
in the pathogenesis of sarcoidosis. We investigated serum levels of these cytokines in a large multi-ancestral sarcoidosis
population to determine correlations between cytokine levels and disease phenotypes.
Methods: We studied serum samples from 98 patients with sarcoidosis, including 71 patients of African-American ancestry
and 27 patients of European-American ancestry. Serum type I IFN was measured using a sensitive reporter cell assay and
serum TNF-a was measured using a commercial ELISA kit. Clinical data including presence or absence of neurologic, cardiac,
and severe pulmonary manifestations of sarcoidosis were abstracted from medical records. Twenty age-matched non-
autoimmune controls were also studied from each ancestral background. Differences in cytokine levels between groups
were analyzed with Mann-Whitney U test, and correlations were assessed using Spearman’s rho. Multivariate logistic
regression models were used to detect associations between cytokines and clinical manifestations.
Results: Significant differences in cytokine levels were observed between African- and European-American patients with
sarcoidosis. In African-Americans, serum TNF-a levels were significantly higher relative to matched controls (P=0.039), and
patients with neurologic disease had significantly higher TNF-a than patients lacking this manifestation (P=0.022). In
European-Americans, serum type I IFN activity was higher in sarcoidosis cases as compared to matched controls, and
patients with extra-pulmonary disease represented a high serum IFN subgroup (P=0.0032). None of the associations
observed were shared between the two ancestral groups.
Conclusions: Our data indicate that significant associations between serum levels of TNF-a and type I IFN and clinical
manifestations exist in a sarcoidosis cohort that differ significantly by self-reported ancestry. In each ancestral background,
the cytokine elevated in patients with sarcoidosis was also associated with a particular disease phenotype. These findings
may relate to ancestral differences in the molecular pathogenesis of this heterogeneous disease.
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Introduction
Sarcoidosis is a severe multi-system disease of uncertain
etiology, thought to be triggered by the aberrant activation of
the immune system. The respiratory system is the most frequently
involved organ system, with the thorax being afflicted in more
than 90% of patients [1]. In extra-pulmonary sarcoidosis,
granulomatous inflammation can permeate almost any part of
the body, including the skin, liver, joints, muscles, heart, and
nervous system [2]. The disease course in sarcoidosis can be acute
or chronic, and those subjects with a chronic, progressive course
typically carry a worse prognosis with more severe organ system
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29126involvement. Those who present with the Lofgren’s syndrome
(hilar adenopathy, arthritis, and erythema nodosum) typically
follow an acute self-limited course; however this subgroup
represents a minority of patients with sarcoidosis [1]. It is not
yet possible to predict disease course, severity, or the type of organ
system involvement for the majority of sarcoidosis patients.
Sarcoidosis treatments generally aim to delay or prevent disease
progression, which can ultimately lead to organ failure, but as of
yet there is not cure for this condition.
Granulomatous inflammation at sites affected by sarcoidosis is
marked by the infiltration of activated monocytes, macrophages,
and CD4+ helper T cells. Despite this accumulation of immune
cells in affected tissues, circulating lymphocyte counts are
significantly reduced in many patients [3]. It seems likely that
cytokines and chemokines in sarcoidosis not only orchestrate the
formation of granulomas locally but also contribute to the egress of
immune cells from the peripheral circulation into inflamed tissues.
Tumor necrosis factor (TNF)-a and type I interferon (IFN) are
cytokines with important roles in coordinating immune reactions,
and potentially contribute to the local and systemic inflammatory
processes underlying sarcoidosis pathogenesis.
Alveolar macrophages are well recognized as capable of the
release of proinflammatory factors including interleukin (IL) 1 and
TNF-a that potentially contribute to the underlying disease
pathology and inflammation in patients with pulmonary sarcoid-
osis [4,5]. TNF-a inhibitors are currently used off-label in
sarcoidosis. Small trials and dozens of case studies, including our
own, have described mostly positive results [6–12]. Infliximab, a
chimeric anti-TNF-a monoclonal antibody, was well tolerated and
effectively improved index organ involvement without disease
recurrence in a case study of refractory sarcoidosis (nine cases of
patients who failed to improve despite moderate-to-high predni-
sone doses) [12]. Long-term follow-up of these patients—as well as
some patients treated with the humanized anti-TNF-a monoclonal
antibody, adalimumab—revealed that although TNF inhibition is
generally safe and effective, it is not curative [13]. In addition,
some patients relapsed upon discontinuation of these medications
(unpublished data, Sweiss NJ).
Similar to TNF-a, type I IFN has also been implicated in
sarcoidosis pathogenesis. Type I IFN plays a critical role in viral
defense mechanisms and bridges the innate and adaptive immune
defenses [14]. IFN-a contributes to the regulation of immune cells,
such as T cells (CD4+, regulatory T cells, and T helper cells), B
cells, and dendritic cells [14]. In addition, IFN promotes Th1
immune responses implicated in sarcoidosis pathogenesis. In-
creased type I IFN signaling has been implicated in a number of
autoimmune diseases, including systemic lupus erythematosus
[15], Sjogren’s syndrome [16,17], inflammatory myopathies [18],
and scleroderma [19]. However, due to its antiviral and
immunnomodulatory capacity, IFN-a has also been used to treat
chronic hepatitis C (HCV) and recombinant IFN is used as an
immunomodulatory treatment for some cancers including mela-
noma and renal cell carcinoma [20].
Despite the therapeutic utility of IFN-a and TNF-a antagonists
in human diseases, these agents have been implicated in the
induction of autoimmune diseases [21], including sarcoidosis, with
more than 30 cases of TNF-a antagonist-induced sarcoidosis
reported [22–26]. Similarly, when used to treat HCV, recombi-
nant IFN-a has been associated with sarcoidosis onset [27].
Sarcoidosis has been reported in nearly 100 patients infected with
HCV, though not all cases have been directly linked to anti-HCV
therapies, and pre-existing sarcoidosis was reactivated in some
instances [28–33]. A link between these two diseases may exist and
warrants further investigation. HCV treatment usually consists of
6–12 months of pegylated IFN-a and ribavirin therapy, which
elicit response rates of 40% or more [34,35]. Together, these two
agents increase the Th1-driven immune response, which may
account for the onset of sarcoidosis in patients being treated for
HCV. Fortunately, most cases of IFN-a-induced sarcoidosis are
acute, with cutaneous manifestations that usually disappear
spontaneously following the discontinuation of IFN-a and
ribavirin.
Physiological crosstalk between TNF-a and IFN-a pathways has
been reported. For example in the autoimmune diseases juvenile
idiopathic arthritis and Sjogren’s syndrome, treatment with anti-
TNF-a therapy increased IFN-a signaling in peripheral blood
[36,37]. These findings are supported by in vitro studies, which
demonstrated that TNF-a regulates IFN-a expression by inhibit-
ing the generation of IFN-a-producing dendritic cells [36].
Given the likely role of TNF-a and IFN-a in sarcoidosis
pathogenesis and the urgent need for biomarkers predictive of
sarcoidosis phenotype and disease activity, the aim of the present
study was to detect associations between serum TNF-a and IFN-a
levels and disease phenotypes in different ancestral populations.
We hypothesize that such information will shed light on the
immune system abnormalities which characterize sarcoidosis, and




Cytokines were measured in serum samples from 98 patients
with sarcoidosis from the Translational Research Initiative in the
Department of Medicine (TRIDOM) registry at the University of
Chicago. Seventy-one patients were of African-American descent
and 27 patients were of European-American ancestry. Clinical
data for the sarcoidosis cases were abstracted from medical records
including neurologic, cardiac, and severe pulmonary involvement,
as well as treatment with TNF-a inhibitors. Neurologic and
cardiac involvement was defined as compatible imaging or biopsy
studies of the affected organ system in a patient with confirmed
sarcoidosis. Severe pulmonary involvement was defined as having
a forced vital capacity (FVC) of less than 50% of predicted on
pulmonary function testing in a patient with confirmed sarcoidosis.
Although patients with ,50% FEV1 or DLCO may also be
considered severe, we did not take these clinical measures into
account for this analysis. We define neurologic, cardiac and severe
pulmonary involvement as distinct subphenotypes. In addition, we
screened our patients for hepatic involvement and other liver
diseases. Among the 98 patients, two individuals were hepatitis C
virus positive and three had hepatic sarcoidosis. Clinical and
demographic characteristics of the sarcoidosis patient population
studied are summarized in Table 1. Age, sex, and self-reported
ancestral background were recorded for all subjects in the study.
Serum samples were also obtained from a control cohort of 40
age-matched individuals from the TRIDOM registry screened for
the absence of autoimmune diseases and the use of corticosteroids
for other systemic diseases, as well as significant cardiac,
pulmonary or neurologic diseases by medical record review (20
African-American, 20 European-American individuals). The study
was approved by the University of Chicago Institutional Review
Board, and all subjects provided informed consent.
Reporter cell assay for type I IFN in serum
The assay for type I IFN is fully described and validated in prior
reports [15,38]. Briefly, reporter cells (WISH cells, ATCC #CCL-
25) were used to measure the capacity of sera to induce the
IFN-Alpha and TNF-Alpha Levels in Sarcoidosis
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50% patient serum for 6 hours, they were lysed, and cDNA was
synthesized from total cellular mRNA extracted from the lysates.
Real-time PCR was then used to quantify IFN-induced gene
expression using the SYBR Green fluorophore system. Primers for
the type I IFN-regulated myxovirus resistance 1 (MX1), RNA-
dependent protein kinase (PKR), and interferon-induced protein
with tetratricopeptide repeats 1 (IFIT1) genes were used, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was ampli-
fied as a housekeeping gene expression from which to calculate
relative expression values. Relative expression levels of these type I
IFN-inducible genes were then compared to data from 141 healthy
control individuals distinct from the 40 controls tested in this study
[15], and the number of standard deviation (SD) above the mean
of this control population was used as the type I IFN activity value.
For further description of the type I IFN activity score, please see
ref. [15]. This assay has been highly informative when applied to
multiple different human autoimmune disease populations
[15,17,18].
TNF-a ELISA measurement
TNF-a was measured in serum samples using the human
monoclonal TNF-a ELISA (Pierce, Rockford, IL), according to
the manufacturer’s instructions. Our control samples performed
similarly to control subject data reported for this ELISA kit in the
past (mean of all 40 controls=1.78 pg/mL, SD=2.46 pg/mL).
Statistical analysis
Cytokine data were non-normally distributed, and differences in
cytokine levels between groups were analyzed using the non-
parametric Mann-Whitney U test. Correlations were assessed
using Spearman’s rho. For each ancestral group, we used
multivariate logistic regression modeling to detect associations
between cytokine levels and sarcoidosis organ subphenotypes, and
to evaluate for confounding effects of age, sex, and the use of anti-
TNF-a therapy. Cytokine data were log transformed prior to be
used in the multivariate models. Initial models were tested with
one of the three sarcoidosis subphenotypes as the outcome
variable, and using age, sex, use of anti-TNF-a therapy, and the
other two subphenotypes as predictor variables. Follow-up models
discarded predictors with a p value of .0.2, and predictor
variables with p,0.05 in follow-up analyses were considered
significant. P values shown in the paper are uncorrected for
multiple comparisons.
Results
Serum cytokine levels in patients with sarcoidosis differ
by ancestry
No cytokine differences were observed according to gender, but
significant differences in TNF-a level were found between
sarcoidosis patients of different ancestral backgrounds. As shown
in Figure 1, African-American patients had higher TNF-a levels
than European-American patients (P=0.036). A non-significant
trend was also observed toward higher type I IFN activity in
European-American sarcoidosis patients as compared to African-
American patients (P=0.094). Controls from each ancestral
background were also assessed. African-American sarcoidosis
patients had higher TNF-a levels than matched controls
(P=0.039, Figure 1), but no significant difference in type I IFN
activity was observed between cases and controls. European-
American sarcoidosis patients had higher type I IFN activity than
did matched controls (P=0.031, Figure 2), but demonstrated no
significant difference in TNF-a levels. Notably, no major changes
were observed when the subjects on TNF-a inhibitors were
removed (Figure S1), suggesting that the correlations we observed
between cytokine levels and clinical phenotypes were not due to
the treatment with TNF-a inhibitors.
Multivariate analysis to detect associations between
serum cytokine levels and sarcoidosis subphenotypes
We used multivariate logistic regression modeling to detect
associations between cytokine levels and presence or absence of
neurologic, cardiac, and severe pulmonary involvement. Given the
differences observed above in cytokine levels between ancestral
backgrounds, regression models were tested in each ancestral
background separately. In African-American patients with sar-
coidosis, neurologic disease was associated with higher TNF-a
(P=0.041) and male sex (P=0.049), and these two associations
were independently significant (Table 2). Also in African-
American patients, severe pulmonary disease was associated with
use of anti-TNF-a agents, and there was a non-significant trend
toward association with male sex (P=0.06). In European-
Americans, no significant associations were observed in logistic
regression models (data not shown), although this may be due to
the small number of subjects available in this ancestral
background. We did observe non-significant trends toward
Table 1. Summary of demographic and clinical information
for the sarcoidosis patients included in the study.
Characteristics
(N=98)
Age, mean (range) 49.6 (20–83)
Ancestry and Gender, n (%)
European American - Male 9 (9.2)
European American - Female 18 (18.4)
African American – Male 12 (12.2)
African American -Female 59 (60.2)




FVC ,50, n (%) 18 (18.4)
Pts on Corticosteroids, n (% of pts with data available)
Yes 66 (73.3)
No 22 (24.4)
Past steroid use 2 (2.2)
Unknown, n (% of total pts) 8 (8.1)
Pts on DMARDs, n (% of pts with data available)
Yes 58 (65.2)
Methotrexate, n (% of pts with data available) 26
Others (e.g., azathioprine, leflunomide) 10
Unknown 22
No 31 (34.8)
Unknown, n (% of total pts) 9 (0.9)
Pts on TNF inhibitors, n (% of pts with data available)
Yes 20 (20.4)
No 78 (79.6)
Pts: patients; DMARDs: disease-modifying antirheumatic drugs.
doi:10.1371/journal.pone.0029126.t001
IFN-Alpha and TNF-Alpha Levels in Sarcoidosis
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type I IFN in European-American patients. No significant
differences were observed in serum type I IFN and TNF-a levels
related to treatment with DMARDs (disease-modifying antirheu-
matic drugs) or corticosteroids (P.0.05 in each ancestral
background, data not shown), and incorporating these data in
the regression models did not significantly alter the observed
cytokine associations.
Quantitative analysis of cytokine levels in sarcoidosis
subphenotypes
Guided by the logistic regressions above, we analyzed
quantitative cytokine levels in subgroups suggested by the logistic
regression models. In African-Americans, quantitative TNF-a
levels were higher in sarcoidosis with neurologic disease compared
to patients lacking this manifestation (P=0.022) and to African-
American controls (P=0.0030, Figure 3), with the same patterns
maintained when the few patients on TNF-a inhibitors were
removed (Figure S1). In European-Americans, we found higher
type I IFN levels in the group of patients with extra-pulmonary
disease compared to patients with lung-limited disease (P=0.037)
and to European-American controls (P=0.0032, Figure 4). In
addition, the involvement of either central (CNS) or peripheral
nervous systems, as well as the occurrences of a depressed ejection
fraction (EF) and/or chronic heart failure (CHF) did not appear to
affect the observed association trends. Whether these findings can
be explained by differences in treatment is unknown and warrants
further attention.
Discussion
To our knowledge, this study is the first to demonstrate ancestral
and subphenotype correlations with serum cytokine levels in
patients with sarcoidosis. The cytokine which demonstrated
significant differences in each ancestral background was also
associated with a particular subphenotype. That these associations
were distinct by ancestry is intriguing, as there are well-known
differences in the prevalence of both sarcoidosis and of particular
subphenotypes within sarcoidosis in different ancestral populations
[39]. It is possible that the molecular pathogenesis of sarcoidosis
also differs significantly by ancestry, and that the cytokine
abnormalities we have detected reflected some of the differences
in pathogenesis in this heterogeneous disease. If the ancestral
differences in sarcoidosis pathogenesis can be understood in
greater detail, personalized therapy may become possible, and
cytokines and anti-cytokine therapies would likely be important in
these treatment decisions.
Although the search for serum biomarkers of neurosarcoidosis
had not been previously successful, a recent study found that levels
ofthe soluble IL-2 receptorincerebrospinal fluid(CSF)mayassist in
diagnosing patients with or susceptible to neurosarcoidosis [40].
Serum biomarkers of neurologic involvement would also be of great
utility. Our data suggest that serum TNF-a may provide some
diagnostic information regarding neurologic disease in African-
American sarcoidosis patients. Although serum TNF-a would not
likely be useful as a single indicator, our results here support its
potential use in predictive algorithms. In our own, unpublished
clinical experience, neurosarcoidosis is particularly responsive to
anti-TNF-a therapy when compared with other sarcoidosis
phenotypes. This observation may be related to the elevated serum
TNF-a level we found in this sarcoidosis phenotype.
We found high serum type I IFN in a subgroup of patients
defined by ancestry and specific disease manifestations. This result
is very interesting, as sarcoidosis is reported to result from
exogenous administration of type I IFN as a therapy for
malignancy or chronic viral infection, and it is possible that
higher endogenous level of type I IFN could be related to disease
susceptibility as well. This model seems to also apply to systemic
lupus erythematosus, as many of the genetic polymorphisms
associated with disease susceptibility are also associated with
increased serum IFN level [41–43].
It is important to note that all patients included in our study
were evaluated at a tertiary care center, with the majority treated
Figure 1. Serum TNF-a levels in sarcoidosis patients and
controls in each ancestral background. Lines represent the
median, boxes show the interquartile ranges, and error bars show the
10
th and 90
th percentiles with dots indicating outliers. P-values by
Mann-Whitney U test.
doi:10.1371/journal.pone.0029126.g001
Figure 2. Serum type I IFN activity in sarcoidosis patients and
controls in each ancestral background. Lines represent the
median, boxes show the interquartile ranges, and error bars show the
10
th and 90
th percentiles with dots indicating outliers. P-values by
Mann-Whitney U test.
doi:10.1371/journal.pone.0029126.g002
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HCV and two others had a history of prior corticosteroid use.
Though other liver diseases have been associated with increased
circulating TNF-a level [44], we did not observe unusually
elevated TNF-a among our three patients with hepatic sarcoidosis
and two patients with positive hepatitis C virus infection.
Furthermore, 65.2% of patients were on DMARDs (mostly on
methotrexate, with a small proportion of patients on hydroxy-
chloroquine, leflunomide, azathioprine, and cellcept), and 20.4%
were receiving TNF inhibitors (Table 1). Notably, the majority the
patients treated with DMARDs (82.8%) were on concomitant
corticosteroid therapy. We did not observe any overall effects of
these treatments on cross-sectional cytokine levels measured in this
paper. We cannot rule out the possibility that these treatments
could have some impact upon cytokine levels, however these
treatments were not responsible for the differences in cytokine
levels we observed. Our analyses did not take disease duration into
consideration, which may also impact levels of circulating
cytokines in patients with sarcoidosis. Whether TNF-a and type
I IFN are persistent and stable biomarkers also warrants
investigation.
Table 2. P values obtained from stepwise multivariate logistic regression modeling of sarcoidosis phenotypes in African-American
sarcoidosis patients.
Predictor variables Outcome variables in initial model Outcome variables in follow-up model
Neuro Cardiac Severe Pulm Neuro Cardiac Severe Pulm
Neuro X 0.15 .0.2 X 0.29 X
Cardiac 0.13 X .0.2 0.14 X X
Severe Pulm .0.2 .0.2 X X X X
Male Sex 0.062 .0.2 0.06 0.049 X 0.06
Age .0.2 .0.2 .0.2 X X X
Anti-TNF-a .0.2 .0.2 0.02 X X 0.026
IFN .0.2 .0.2 .0.2 X X X
TNF 0.042 0.14 .0.2 0.041 0.19 X
Neuro, cardiac, and severe pulm: presence of neurologic, cardiac, and severe pulmonary involvement respectively, as defined in the methods section;
Anti-TNF-a: patient using anti-TNF-a therapy at the time of the study.
IFN and TNF: log transformed values from the serum TNF-a and type I IFN activity assays;
X: not included in the model as a predictor;
numeric values shown indicate the p-value for that variable in the specified logistic regression model.
doi:10.1371/journal.pone.0029126.t002
Figure 3. Serum TNF-a levels in African-American controls and
sarcoidosis patients stratified by presence or absence of
neurologic involvement. Lines represent the median, boxes show
the interquartile ranges, and error bars show the 10
th and 90
th
percentiles with dots indicating outliers. P-values by Mann-Whitney U
test.
doi:10.1371/journal.pone.0029126.g003
Figure 4. Serum type I IFN activity in European-American
controls and sarcoidosis patients stratified by presence or
absence of extra-pulmonary manifestations. Lines represent the
median, boxes show the interquartile ranges, and error bars show the
10
th and 90
th percentiles with dots indicating outliers. P-values by
Mann-Whitney U test.
doi:10.1371/journal.pone.0029126.g004
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between disease sub-phenotypes and serum levels of TNF-a and
type I IFN, which were distinct in different ancestral backgrounds.
Particularly, our findings appeared to support that severe
sarcoidosis phenotypes have distinct pathogenesis among racial
groups, though a larger cohort of patients from different
populations may be necessary to confirm this observation.
Therapies directed at both of these cytokines are either already
in use (TNF-a) or in clinical trials (type I IFN) in autoimmune
disease. The results of our study may help guide the potential
application of these agents in sarcoidosis, as our results suggest that
each of these cytokines may be more important in a particular
group of patients with sarcoidosis. Future work, including
additional independent cohorts and longitudinal studies, as well
as the availability of more comprehensive clinical data (e.g.,
granuloma burden) will help translate these findings into
diagnostic and prognostic algorithms in sarcoidosis.
Supporting Information
Figure S1 Association results after removing patients
on TNF-a inhibitors. (A) Serum type I IFN activity is elevated
in European-American patients relative to controls; (B) Serum
TNF-a level is elevated in African-American patients relative to
controls; (C) Serum type I IFN activity is elevated in European-
American patients with extra-pulmonary manifestations relative to
controls; (D) Serum TNF-a level is elevated in African-American
patients with neurologic sarcoidosis relative to controls, as well as
in African-American patients with neurologic sarcoidosis relative
to patients without neurologic sarcoidosis.
(TIF)
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